The medical community is buzzing with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 receptor that’s demonstrating significant promise in clinical trials for addressing obesity. Unlike some available weight loss treatments, retatrutide appears to deliver a greater substantial loss in body mass and improve metabolic markers, part